In an innovative advancement, scientists at King’s College London have highlighted the potential of using IgE antibodies as a viable strategy against HER2-expressing cancers, particularly those resistant to conventional medications. Unlike IgG, the current treatment focus, IgE antibodies activate distinct immune pathways to target cancer cells directly.
About the Author
